Technical Analysis for TLC - Taiwan Liposome Company, Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
5.9 | -0.34% | -0.02 |
TLC closed down 0.34 percent on Thursday, December 13, 2018, on 6 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| See historical TLC trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Dec 13 | Hot IPO Pullback | Bullish Swing Setup | 0.00% |
| Dec 13 | Narrow Range Bar | Range Contraction | 0.00% |
| Dec 12 | Hot IPO Pullback | Bullish Swing Setup | -0.34% |
| Dec 12 | Outside Day | Range Expansion | -0.34% |
| Dec 11 | Hot IPO Pullback | Bullish Swing Setup | -3.28% |
| Dec 11 | Narrow Range Bar | Range Contraction | -3.28% |
| Dec 11 | NR7 | Range Contraction | -3.28% |
| Dec 11 | Inside Day | Range Contraction | -3.28% |
| Dec 10 | Bearish Engulfing | Bearish | -1.83% |
| Dec 10 | Outside Day | Range Expansion | -1.83% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
aiwan Liposome Company, Ltd., a biopharmaceutical company, engages in the research, development, and commercialization of lipid-based pharmaceutical products. The company offers products in the areas of oncology, ophthalmology, peripheral arterial disease, fungal infection, anesthetic, and arthritis indications. Its products include Lipotecan, an anti-cancer camptothecin drug; Doxisome, a liposomal encapsulated formulation of doxorubicin; TLC178, a liposomal encapsulated formulation of vinorelbine; ProDex, an ophthalmic drug for the treatment of macular edema; ProFlow, an emulsion form of prostaglandin E1; AmBiL, a liposomal encapsulated formulation of amphotericin B; TLC198, a liposomal encapsulated bupivacaine, enabling the sustained release of a constant amount of local anesthetic; and TLC599, a corticosteroid encapsulated in lipid based drug delivery system for the treatment of inflammation caused by arthritis. The company was founded in 1997 and is headquartered in Taipei City, Taiwan.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 0 bearish and 5 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 8.16 |
| 52 Week Low | 5.8 |
| Average Volume | 9,508 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 0.0 |
| 20-Day Moving Average | 0.0 |
| 10-Day Moving Average | 6.0935 |
| Average True Range | 0.5049 |
| ADX | 0.0 |
| +DI | 42.5611 |
| -DI | 9.5899 |
| Chandelier Exit (Long, 3 ATRs ) | 6.6453 |
| Chandelier Exit (Short, 3 ATRs ) | 7.3147 |
| Upper Bollinger Band | 0.0 |
| Lower Bollinger Band | 0.0 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.0 |
| MACD Line | -0.0476 |
| MACD Signal Line | -0.0176 |
| MACD Histogram | -0.03 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.90 | ||||
| Resistance 3 (R3) | 5.90 | 5.90 | 5.90 | ||
| Resistance 2 (R2) | 5.90 | 5.90 | 5.90 | 5.90 | |
| Resistance 1 (R1) | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 |
| Pivot Point | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 |
| Support 1 (S1) | 5.90 | 5.90 | 5.90 | 5.90 | 5.90 |
| Support 2 (S2) | 5.90 | 5.90 | 5.90 | 5.90 | |
| Support 3 (S3) | 5.90 | 5.90 | 5.90 | ||
| Support 4 (S4) | 5.90 |
